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Ltd. This is an open access article undAbstract Objective: The purpose of the study is to report and to analyze the complications
following intratympanic injections (ITI) of steroids. The occurrence rate of complications at
different ITI sites, four quadrants of eardrum, was also compared.
Methods: A retrospective clinical review in a medical center. Each patient received ITI twice in
a week for 2e3 consecutive weeks as a salvage therapy for sudden sensorineural hearing loss.
Post-injection complications, especially transient dizziness and vertigo, were recorded. Pa-
tients with acute or chronic vertigo episodes in 1 month were excluded.
Results: A total of 59 patients with sudden sensorineural hearing loss and a total of 278 times
of ITI were performed in 1 year. The post-injection complications included pain, tongue numb-
ness, transient dizziness, vertigo, tinnitus, and a small persistent perforation. There was no
significant difference in the occurrence of these complications between the injections sites
on the 4 quadrants of the tympanic membrane. However, there was statistical significance
in the post-injection vertiginous episode after IT injections to posterior-inferior quadrant
(Q3) and posterior-superior quadrant (Q4) compared to anterior-superior quadrant (Q1) and
anterior-inferior quadrant (Q2) (P Z 0.0113).t of Otolaryngology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei,
; fax: þ886 2 23946674.
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14 Y.-C. Liu et al.Conclusion: IT injection is recommended to be applied to the Q2 since the Q1 and Q4 injections
are more likely to induce the adverse effect of tongue numbness, while the Q3 and Q4 areas
are more likely to induce post-injection vertigo.
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Corticosteroids are widely used for the treatment of
Me´nie`re’s disease, sudden sensorineural hearing loss
(SSNHL), autoimmune inner ear disease, and tinnitus. Oral
treatment with steroid was reported to have 88% adverse
effects, such as increasing requirements for insulin or oral
hypoglycemic agent (OHA) in patients with diabetes melli-
tus (DM), increased thirst, and sleep or appetite changes.
The intratympanic injection (ITI) was first used by Itoh to
treat patients with Me´nie`re’s disease in 1991.1 Silverstein
was the first to use intratympanic steroids for the treat-
ment of SSHNL in 1996. This method decreases the side
effect of systemic steroid administration and leads to
higher concentrations of the injected drug in the inner ear.
Recently, many studies have shown the efficacy of corti-
costeroid use on the cochlear function in both human and
animal models.2 Despite wide-ranging investigations, only
minimal information focused on the adverse effects
induced by ITI of steroid. The complications of ITI include
transient dizziness, injection pain, a burning sensation,
increasing tinnitus, post-injection vertigo, tongue numb-
ness, and a small perforation of the eardrum.3 The most
common side effect is transient dizziness, injection site
pain, and a burning sensation. The character of post-
injection vertigo has not been described in detail. This
article will focus on the adverse effects of ITI and a char-
acteristic description of post-injection vertigo. In order to
prevent possible annoying side effects,4,5 previous articles
suggested injection of the solution into the posterior-
inferior quadrant, via narrow-gauge spinal needle, to fill
the middle ear space.4 However, there is still no consensus
to it.Materials and methods
Patient selection
This retrospective clinical study was performed from
January 1st, 2013 to December 25th, 2013 in a medical
center. It included 59 patients with idiopathic sudden
sensorineural hearing loss (ISSHL). Six out of 59 patients had
severe vertigo attack along with sudden hearing loss for the
initial 2 days, then vertigo subsided and followed by mild to
moderate disequilibrium. All intratympanic steroid injected
were used as a salvage treatment when primary treatment
with oral steroid failed to improve hearing loss and tinnitus
completely. The exclusion criteria are patients under active
treatment for recurrent vertigo before ITI.Intratympanic injection technique
The ITI procedure has been approved by ethic committee of
this hospital as a standard procedure to treat sudden
deafness. Before the procedure, an informed consent with
a clear explanation of the different injection sites, the risks
and benefits, and the local anesthesia (although there was
evidence that the local anesthesia before ITI is not always
necessary3), was obtained. Since there are no standard
protocol of ITI in this hospital regarding how many in-
jections should be administered to one treatment course,
the injection times was determined by the two senior au-
thors. One of them injected 4 times in a 2-week period and
the other 6 times in a 3-week period. In total, 38 patients
were injected 4 times and 21 were injected for 6 times,
which made the total injection times of 278.
Each patient received ITI twice in a week, separated by
at least 2 days, for 2 or 3 consecutive weeks. Because this is
a retrospective review, the injection sites and criteria were
not pre-designed. For both senior authors who did the in-
jection, the sites were mainly dependent on the condition
of the eardrum. Most often, the anterior inferior Q will be
selected, other alterative sites was chosen under special
conditions such as an unhealed perforation by prior injec-
tion or blot clot covering the preferred injection sites. We
defined Q1 as the anterior-superior quadrant, Q2 as the
anterior-inferior quadrant, Q3 as the posterior-inferior
quadrant, and Q4 as the posterior-superior quadrant. In-
jections were administered in the out-patient clinic by the
senior authors under operating microscope. Extreme care
was taken to slowly inject the steroid into middle ear to
avoid injury to the underlying structures despite of
different injection sites. We used 20% lidocaine spray as the
local anesthetic agent, which is applied and fills the
external auditory canal 5 min before injections. In order to
prevent a caloric reaction, we asked patients to warm up
the injection agent by holding the syringe with drugs in
their palm for 5e10 min to warm it to body temperature.
The patient was asked to lie in a supine position, with the
head turned 45 toward the unaffected ear. Medication was
injected through 1 of the 4 different quadrants of the
tympanic membrane with a BectoneDickinson (BD) spinal
needle (27 G, 3.50 in., 0.64 mm  90 mm). Once the IT
injection was administered, the patient was asked to keep
the same position for 30 min to provide maximal absorption
of the medication through the round window. Patients were
asked not to speak or swallow to prevent drug leakage
through the Eustachian tube. After each injection, patients
were asked to report if they perceived intolerable pain,
vertigo, or any discomfort immediately. In addition, at the
next office hour, patients were requested to describe and
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We also checked the pure-tone audiometry before the
course of IT injection, weekly during the course and 1 week
after completion of the treatment course. Outcome
improvement is defined as the difference of 5 frequencies
(256 Hz, 512 Hz, 1024 Hz, 2048 Hz, and 4096 Hz). Average
hearing level improved more than 10 dB after ITI.
Injection agent
The medication we chose was Rinderon Injection (Beta-
methasone Disodium Phosphate 5.3 mg/mL, as Betame-
thasone 4 mg/mL). The dosage was about 0.4e0.8 mL into
the middle ear space for each injection, according to
Clinical Practice Guideline.4
Measures and statistical analysis
The crew asked patients to report (immediately and 30 min
after ITI) if there were any discomforts after ITI, such as
vertigo, intolerable pain, tinnitus, ear fullness, burning
sensation, or tongue numbness. This was repeated in the
next office hour. We were also wary of eardrum perfora-
tions. We calculated the percentage of complications and
also analyzed the relationship between injection sites at
the tympanic membrane and complications, using Chi-
squared test by SPSS 2.0.
Results
Complications after ITI
There were 59 patients (26 male, 33 female, average age
57.2 years old, left ear 29 cases, right ear 30 cases) who
received ITI (278 times in total). The most common injec-
tion site was the anterior-inferior quadrant (Q2), 120 times
(43.2%), followed by the posterior-inferior quadrant (Q3),
the anterior-superior quadrant (Q1), and the posterior-
superior quadrant (Q4). The injection times and percent-
ages are 92 (33.1%), 35 (12.6%), and 31 (11.2%) respectively.
The injection site depends on the different technique of
the senior authors and the prior injection conditions such as
clot or perforation. ITI was used as initial therapy for 17
(28.8%) patients. Steroid ITI was used as salvage therapy for
42 (71.2%) patients. Twenty-five (42.3%) cases had hearing
improvement after ITI.
Increasing tinnitus was noted 15 out of 278 times (about
5.4%) after ITI. The transient dizziness and post-injection
vertigo were noted 47 times (16.9%) and 5 times (1.8%),
respectively, after injection. Most patients who received ITI
underwent only mildly painful sensations, about 211 times
(75.9%). There was one female who suffered from severe
pain after ITI and refused further ITI therapy. The patients
with underlying diseases, such as diabetes mellitus (DM),
peripheral neuropathy, or a history of nasopharyngeal
cancer status post-irradiation therapy or chronic otitis
media with eardrum thickening, reported less pain during
injection. The symptom of tongue numbness was reported
by 2 patients, about 0.7%. The injection sites were the Q1
and Q4, respectively. One case had a small eardrumperforation after 6 times of ITI. A previous article reported
that persistent tympanic membrane perforations are rare
and most of them lasting up to 6 months.4 The perforation
site was on the Q2 area, and the wound healed spontane-
ously after 4 weeks of out-patient department (OPD)
follow-up. The hearing recovery rate in our article is about
42.3%. The recovery rate is higher than that in a previous
article (27.5%).5
Post-ITI vertigo cases
The acute onset transient dizziness episodes are quite
frequent. They ranged from disequilibrium for several
seconds to lightheadedness for a few minutes. The duration
rarely lasted longer than 10 min. It does not affect the
patient’s ability to walk or his behavior. It was relieved
spontaneously after a few minutes of rest.
Five patients had post-injection vertigo. They did not
suffer from vertigo attack until 20e30 min after ITI, espe-
cially when getting up. We realized that the duration of
post-injection vertigo ranged from 40 min to 5 h, and it was
accompanied by persistent horizontal nystagmus to the
unaffected ear. The visual suppression was positive in all
five patients. Two patients had rotatory nystagmus to the
left, and one patient had rotatory nystagmus to the right.
The detailed data of these 5 patients are listed in Table 1.
Two out of five patients recovered after ITI. Case 1 without
previous medical history has a hearing improvement from
an average hearing level of 85 dBe50 dB. Case 2 has a
history of breast cancer, status post operation 2 years ago,
now under hormone therapy. She also has hearing
improvement from an average hearing level of 79 dBe7 dB.
The other 3 cases did not have obvious hearing
improvements.
Injection site and post ITI dizziness and vertigo
As shown in Table 2, the Q1 statistical accumulation showed
8 patients out of 35 patients, 22.9%, who experienced
transient dizziness after ITI. The Q2 statistical accumula-
tion showed 20 patients out of 120 patients, 16.7%, who
experienced transient dizziness after ITI. The Q3 statistical
accumulation showed 13 patients out of 92 patients, 14.1%,
who experienced transient dizziness after ITI. The Q4 sta-
tistical accumulation showed 6 patients out of 31 patients,
19.4%, who experienced transient dizziness after ITI.
Although a difference in the percentage of transient
dizziness rate is noted in each quadrant, it is not statisti-
cally significant and all P values >0.05.
Comparing the incidence of post-injection vertigo be-
tween the two protocols (4 times in 2 weeks vs.6 times in 3
weeks), the 4 times group is 1.58% and the 6 times group is
1.97%. This is based on injection numbers but not patient
numbers. There is no statistical difference between these
two protocols.
Discussion
The possible pathophysiology of post ITI vertigo is still un-
known. The etiology may be due to the caloric test
response, the lidocaine agent diffused into the inner ear,
Table 1 Five post-injection cases.
Number Age Sex Oral steroid
therapy
Lesion
side ear
Quadrate Rotation Nystagmus
direction
Duration Vomiting Hearing
improvement
1 71 M Yes Right Q3 No Left 2 h 37 min No Yes
2 56 F No Right Q3 Clockwise Left 3 h Yes No
3 81 M Yes Left Q4 Conterclock Right 2 h 20 min Yes No
4 54 M Yes Right Q3 Clockwise Left 5 h Yes No
5 31 F Yes Left Q4 No Right 40 min No Yes
Q3, posterior-inferior quadrant, and Q4, posterior-superior quadrant; M, male; F, female.
Table 2 Injection sites and incidence of post-injection
dizziness or vertigo.
Injection site
(quadrant)
Transient
dizzy rate
Post-injection
vertigo rate
Q1 8/35 (22.9%) 0/35 (0%)
Q2 20/120 (16.7%) 0/120 (0%)
Q3 13/92 (14.1%) 3/92 (3.3%)
Q4 6/31 (19.4%) 2/31 (6.5%)
Q1, anterior-superior quadrant; Q2, anterior-inferior quadrant;
Q3, posterior-inferior quadrant, and Q4, posterior-superior
quadrant.
16 Y.-C. Liu et al.the semicircular canal dehiscence on the middle ear cavity
side or the injection agent irritating the round window. The
caloric response was first described by Robert Barany in
1906. It is a test of the lateral semicircular canals. Vertigo
and nystagmus may be induced immediately by warm and
cold media. The duration is usually within 10 min. The
clinical course is different from what we observed in post-
ITI vertigo, which has much longer vertiginous time with
persistent nystagmus. Besides, we always ask patients to
warm up the steroid agent in the palm for 5e10 min before
injection. Therefore, the Caloric test response is less likely
to be the major explanation of post-injection vertigo.
The lidocaine agent diffused into the inner ear is a
possible explanation of post-injection vertigo, although we
always try to clean the anesthetic agent completely before
injection, we think that there is still possibility that the
residual anesthetic agent may leak and diffuse into the
inner ear. The semicircular canal dehiscence on the middle
ear cavity side is rare and possible, but if such an anomaly
pre-existed, the post-injection vertigo should happen every
time after ITI. It seems it is also not likely to be the etiology
of post-injection vertigo. Another possible etiology of the
post-injection vertigo is the irritation of the round window
by the injection agent, which makes a micro-perilymph
fistula on it. But based on the anatomy and previous
experience of cochlear implantation, round window is
membrane is not so fragile and easily subjected to injury.
Therefore, the micro-fistula is again less likely.
One limitation of the present study is its retrospective
design, which may cause biased result. Also, the injection
done a less favorable condition may be a confoundingfactor in analyzing the post injection complications.
Finally, there is no plausible explanation for the post-
injection prolonged vertigo in 5 patients. However, our
results do suggest that injection on the posterior quadrant
or under less favorable conditions may have higher inci-
dence of vertigo. Therefore these sites should be avoided
whenever possible.
Conclusion
The steroid IT injection performed is suggested to be
applied to the anterior-inferior quadrant (Q2) since the Q1
and Q4 injections are more likely to induce the adverse
effect of tongue numbness, though there was no statistical
significance in our study. The injections to the Q3 and Q4
areas display statistical significance, compared to those of
the Q1 and Q2 areas, with a greater possibility of causing
post-injection vertigo.
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